Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
603392
Rang in Aktien
#3625
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical... Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical firm that handles the entire process from research and development to the production, marketing, and distribution of diagnostic solutions for infectious diseases and various vaccines. The company operates extensively across China and in international markets. Its comprehensive product range offers diagnostic test kits for a multitude of infectious agents, including COVID-19, HIV, HTLV, Hepatitis, EV-71, and Tuberculosis. It also provides specific detection reagents for Hepatitis C and Syphilis. Beyond these, the portfolio includes advanced diagnostic tools such as automated immunoassays, ELISA kits, rapid diagnostic tests, and various chemiluminescence, clinical chemistry, and general immunodiagnostic reagents. Furthermore, Beijing Wantai is a developer and supplier of vaccines for Hepatitis E and human papillomavirus (HPV). The company serves a wide array of clients, including blood banks, hospitals and clinics, specialized reference laboratories, border inspection centers, blood-processing companies, and scientific research institutes. Established in 1991, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is headquartered in China's capital city, Beijing.
Aktienkurs
$3.71
Marktkapitalisierung
$4.69B
Veränderung (1 Tag)
2.44%
Veränderung (1 Jahr)
-51.92%
Land
CN
Handel Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392)
Kategorie
Healthcare
P/B-Verhältnis für Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392)
P/B-Verhältnis zum October 2026 TTM: 2.70
Laut den neuesten Finanzberichten und dem Aktienkurs von Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 2.70. Am Ende des Jahres 2023 lag das P/B-Verhältnis bei 7.46.
P/B-Verlauf für Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. von 2013 bis 2026
P/B-Verhältnis zum Jahresende
| Jahr | P/B-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 2.70 | -64.57% |
| 2024 | 7.63 | 2.35% |
| 2023 | 7.46 | -18.64% |
| 2022 | 9.16 | -63.42% |
| 2021 | 25.05 | -9.41% |
| 2020 | 27.65 | 962.67% |
| 2019 | 2.60 | -10.83% |
| 2018 | 2.92 | -31.74% |
| 2017 | 4.28 | 0.30% |
| 2016 | 4.26 | -22.48% |
| 2015 | 5.50 | -15.25% |
| 2014 | 6.49 | -31.92% |
| 2013 | 9.53 | 0.00% |
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/B-Verhältnis | P/B-Verhältnis-Differenz | Land |
|---|---|---|---|
| 6.251 | 131.26% |
US
|
|
| 13.2547 | 390.37% |
US
|
|
| 4.208 | 55.68% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 128.72% |
NL
|
